SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Terremoto Biosciences, a biotechnology company developing first- and best-in-class targeted therapeutics, today announced the appointment of Charles Baum, M.D., Ph.D., as Chief Executive Officer. Dr. Baum succeeds Peter Thompson, M.D., who will continue to serve as Terremoto’s Board chairperson.
“Chuck has a legacy of successful leadership in precision therapeutics, most recently at Mirati Therapeutics, where under his guidance, the company was transformed and went on to create compelling pipeline value that led to an acquisition by Bristol Meyers Squibb for up to $5.8 billion,” said Thompson. "I’m honored to hand the reins over to him as the leader of Terremoto. His extensive experience in drug development, and proven track record in advancing high-impact medicines, will be instrumental as we continue to develop treatments that promise superior therapeutic benefit to patients."
Terremoto is harnessing the power of an expanded covalent alphabet to create highly targeted therapeutics for a variety of devastating and severe diseases. The company is applying its unique capabilities to develop best-in-class therapies against known drug targets and first-in-class medicines against high value previously undrugged targets in oncology and beyond.
"Terremoto’s compelling science and innovative approach to developing and advancing groundbreaking medicines creates an unmatched opportunity to fundamentally change the treatment paradigm for people with devastating diseases,” said Dr. Baum. “It is a privilege to join the dynamic team at Terremoto as we are well positioned to discover and develop novel treatments that will have a significant impact on people with a variety of significant unmet needs.”
Prior to his tenure at Mirati, Dr. Baum was deeply involved in oncology development at Pfizer, where he was responsible for the development of several major drugs, including Inlyta®, Xalkori®, Ibrance® and Sutent®. While at Schering Plough, he contributed to the development of Temodar® for the treatment of patients with glioblastoma. His career also includes significant academic and clinical positions at prestigious institutions such as Stanford and Emory Universities. Dr. Baum holds an M.D. and a Ph.D. from Washington University School of Medicine and completed his post-graduate training at Stanford University. He has authored more than 50 peer-reviewed publications and holds several patents in the field of medical sciences.
About Terremoto Biosciences
Terremoto Biosciences is a drug discovery and development company creating highly targeted, small molecule medicines with unmatched selectivity, potency and efficacy designed to deliver superior therapeutic benefit to patients. Terremoto is supported by leading investors including OrbiMed, Third Rock Ventures, EcoR1 Capital, Novo Holdings and Cormorant Capital. More information is available at www.terremotobio.com.
